INS1033 / Insmed - LARVOL DELTA

Progress and Anticipated Milestones:…INS1033 (PRNewswire) - "Insmed's second dipeptidyl peptidase 1 (DPP1) inhibitor, INS1033, is currently advancing toward the clinic in rheumatoid arthritis (RA) and inflammatory bowel disease (IBD), with an initial IND filing expected in 2026."

IND • Inflammatory Bowel Disease • Rheumatoid Arthritis